Increased levels of the soluble receptor of interleukin-6 in patients with preeclampsia compared to normotensive pregnant women;Aumento dos níveis do receptor solúvel da Interleucina-6 em pacientes com pré-eclâmpsia em relação a gestantes normotensas

Scientia Medica

Volumn 23, Issue 4, 2013, Pages 213-218

  Hentschke, Marta Ribeiro ^a   Lucas, Luiza Silveira ^a   Krauspenhar, Bruna ^a   Felix, Raisa Perdomo ^a   Sussela, Alex Oliboni ^a   Berlesi, Francine ^a   Poli de Figueiredo, Carlos E ^a   da Costa, Bartira E Pinheiro ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Inflammation; Preeclampsia; Receptors, interleukin 6

Indexed keywords

CREATININE; INTERLEUKIN 6 RECEPTOR; URIC ACID;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL BLOOD; PLACENTA WEIGHT; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; MATERNAL AGE;

EID: 84895767938     PISSN: 18065562     EISSN: 19806108     Source Type: Journal    
DOI: 10.15448/1980-6108.2013.4.14862     Document Type: Article

References (41)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-S22.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-7.
3. Campbell KH, Savitz D, Werner EF, Pettker CM, Goffman D, Chazotte C, Lipkind HS. Maternal Morbidity and Risk of Death at Delivery Hospitalization. Obstet Gynecol. 2013;122(3):627-33.doi: 10.1097/AOG.0b013e3182a06f4e
4. Zhang YP, Liu XH, Gao SH, Wang JM, Gu YS, Zhang JY, Zhou X, Li QX. Risk factors for preterm birth in five Maternal and Child Health hospitals in Beijing. PloS one. 2012;7(12):e52780.
5. Gagliardi L, Rusconi F, Da Frè M, Mello G, Carnielli V, Di Lallo D, Macagno F, Miniaci S, Corchia C, Cuttini M. Pregnancy disorders leading to very preterm birth influence neonatal outcomes: results of the population-based ACTION cohort study. Pediatr Res. 2013;73(6):794-801.
6. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, Thadhani R, Karumanchi SA. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013;32(2):189-201.
7. Chesley LC. Hypertension in pregnancy: definitions, familial factor and remote prognosis. Kidney Int 1980;18(2):234-40.
8. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541-50.
9. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30:S32-7.
10. Jonsson Y, Rubèr M, Matthiesen L, Berg G, Nieminen K, Sharma S, Ernerudh J, Ekerfelt C. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol. 2006;70(1-2):83-91.
11. Takacs P, Grenn KL, Nikaeo A, Kauma SW. Increased vascular endothelial cell production of interleukin-6 in severe preeclampsia. Am J Obstet Gynecol. 2003;188(3):740-4.
12. Gadonski G, LaMarca BBD, Sullivan E, Bennett W, Chandler D,Granger JP. Hypertension Produced by Reductions in Uterine Perfusion in the Pregnant Rat: Role of Interleukin 6. Hypertens. 2006;48(4):711-6.
13. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47.
14. Knüpfer H, Preiss. R. sIL-6R: more than an agonist? Immunol Cell Biol. 2008,86(1):87-91.
15. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zumBüschenfelde KH, Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183(4):1399-406.
16. Sociedade Brasilerira de Cardiologia, Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia. VI Brazilian Guidelines on Hypertension. Arq Bras Cardiol. 2010;95(1 Suppl):1-51.
17. Atalah E, Castillo C, Castro R, Aldea A. Proposal of a new standard for the nutriotional assessment of pregnant women. Rev Med Chil. 1997;125(12):1429-36.
18. Hentschke MR, Poli-de-Figueiredo CE, Costa BEP, Kurlak LO, Williams PJ, Mistry HD. Is the atherosclerotic phenotype of preeclamptic placentas due to altered lipoprotein concentrations and placental lipoprotein receptors? Role of a small for gestational age phenotype. J Lipid Res. 2013;54(10):2658-64. doi:10.1194/jlr.M036699
19. Kadyrov M, Moser G, Rath W, Kweider N, Wruck CJ, Pufe T, Huppertz B. Maternal-placental interactions and fetal programming. Z GeburtshilfeNeonatol. 2013;217(3):88-94. doi: 10.1055/s-0033-1347179. 2013
20. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol. 2007;29(2):151-62.
21. Sargent IL, Borzychowski AM, Redman CW. Immuno regulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2007;14 Spec No 1: 111-7. doi: 10.1016/S1472-6483(10)61465-4
22. Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol. 2013;31:387-411. doi: 10.1146/annurev-immunol-032712-100003
23. a ed. Rio de Janeiro: Elsevier Brasil; 2012.
24. Bernardi F, Guolo F, Bortolin T, Petronilho F, Dal-Pizzol F. Oxidative stress and inflammatory markers in normal pregnancy and preeclampsia. J ObstetGynaecol Res. 2008;34(6):948-51.
25. Schiessl B. Inflammatory response in preeclampsia. Molecular Aspects of Medicine. 2007;28(2):210-9.
26. Zhang Z, Gao Y, Zhang L, Jia L, Wang P, Li H. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. Hypertens Pregnancy. 2013;32(3):270-80. doi:10.3109/10641955.2013.798332
27. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H. Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy. 2009;28(2):190-200.
28. Al-Othman S, Omu AE, Diejomaoh FM, Al-Yatama M, Al-Qattan F. Differential levels of interleukin 6 in maternal and cord sera and placenta in women with pre-eclampsia. Gynecol Obstet Invest. 2001;52(1):60-5.
29. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819.
30. Gaillard J, Pugniere M, Tresca J, Mani J, Klein B, Brochier J. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. Eur Cytokine Netw. 1999;10(3):337-44.
31. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J. 2003;374(Pt 1):1-20.
32. Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160-7.
33. Zhao S, Gu Y, Dong Q, Fan R, Wang Y. Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia. Placenta. 2008;29(12):1024-8. doi: 10.1016/j.placenta.2008.09.011
34. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14(6):705-14.
35. Jones SA and Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta. 2002;1592(3):251-63.
36. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10(6):1992-9.
37. Singh A, Purohit A, Wang DY, Duncan LJ, Ghilchik MW, Reed MJ. IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. J Endocrinol. 1995;147(2):R9-12.
38. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-64.
39. Tilbery CR, Felipe E, Mota IM, Scheinberg MA. Aumento dos receptores solúveis da interleucina-2 na esclerose múltipla. Arq Neuropsiquiatr. 1994;52(2):216-20.
40. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994;300(Pt 2):281-90.
41. Lau SY, Guild SJ, Barrett CJ, Chen Q, McCowan L, Jordan V, Chamley LW. Tumor Necrosis Factor-Alpha, Interleukin-6, and Interleukin-10 Levels are Altered in Preeclampsia: A Systematic Review and Meta-Analysis. Am J Reprod Immunol. 2013;70(5):412-27. doi: 10.1111/aji.12138.